Table 1.
Characteristics of patients with periprosthetic joint infections caused by methicillin-resistant Staphylococcus undergoing 2-stage revision arthroplasties
| No. | Sex | Age | Surgical procedures | CCI | Pathogen | Antibiotic regimen (bone cement g/systemic mg/kg) | Use daptomycin in bone cement at reimplantation (Y/N) | FU (months) | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 65 | DAIR for TKA | 4 | MRSA | DAP 4/DAP 6 | Y | 26 | Infection controlled |
| 2 | M | 51 | THA | 4 | MRSA | DAP 4 + CEF 4/DAP 6 | N | 32 | Infection controlled |
| 3 | M | 72 | DAIR for revision TKA | 5 | MRSE | DAP 4/DAP 6 | Y | 43 | Infection controlled |
| 4 | M | 53 | Revision THA | 2 | MRCoNS | DAP 4 + CEF 4/DAP 6 | N | 42 | Infection controlled |
| 5 | F | 60 | TKA | 3 | MRSA | DAP 4 + CEF 4/DAP 6 | Y | 38 | Infection controlled |
| 6 | F | 80 | DAIR for TKA | 5 | MRSE | DAP 4/DAP 6 | Y | 26 | Infection controlled |
| 7 | M | 66 | DAIR for THA | 3 | MRCoNS | DAP 4/DAP 6 | N | 51 | Infection controlled |
| 8 | M | 44 | DAIR for THA | 2 | MRSE | DAP 4/DAP 6 | N | 42 | Infection controlled |
| 9 | M | 74 | DAIR for TKA | 4 | MRSE | DAP 4/DAP 6 | Y | 25 | Infection controlled |
| 10 | M | 45 | DAIR for THA | 3 | MRSE | DAP 4/DAP 6 | N | 26 | Infection controlled |
| 11 | M | 51 | DAIR for THA | 4 | MRSA | DAP 4/DAP 6 | Y | 44 | Infection controlled |
| 12 | F | 67 | TKA | 5 | MRSA | DAP 4 + CEF 4/DAP 6 | Y | 32 | Infection controlled |
| 13 | F | 86 | TKA | 5 | MRSA | DAP 4 + CEF 4/DAP 6 | Y | 37 | Infection controlled |
| 14 | M | 51 | DAIR for THA | 5 | MRSA | DAP 4/DAP 6 | N | 40 | Infection controlled |
| 15 | F | 86 | TKA | 5 | MRSA | DAP 4 + CEF 4/DAP 6 | Y | 30 | Infection controlled |
| 16 | F | 81 | THA | 3 | MRSA | DAP 4 + CEF 4/DAP 6 | Y | 32 | Infection controlled |
| 17 | M | 81 | DAIR for revision TKA | 5 | MRSE | DAP 4/DAP 6 | Y | 30 | Infection controlled |
| 18 | M | 51 | DAIR for revision THA | 4 | MRCoNS | DAP 4/DAP 6 | N | 31 | Infection controlled |
| 19 | M | 50 | DAIR for THA | 2 | MRSE | DAP 4/DAP 6 | N | 27 | Infection controlled |
| 20 | M | 87 | TKA | 6 | MRSA | DAP 4 + CEF 4/DAP 6 | Y | 24 | Infection controlled |
| 21 | M | 38 | DAIR for THA | 2 | MRSE | DAP 4/DAP 6 | N | 30 | Infection controlled |
| 22 | M | 78 | DAIR for revision THA | 6 | MRCoNS | DAP 4/DAP 6 | Y | 33 | Infection controlled |
DAIR debridement, antibiotics, irrigation and prosthesis retention, CCI Charlson comorbidity index, DM diabetes mellitus, HTN hypertension, CVA cerebral vascular accident, TKA total knee arthroplasty, LC liver cirrhosis, RA rheumatoid arthritis, THA total hip arthroplasty, CAD coronary artery disease, BMI body mass index, HBV hepatic B virus, HCV hepatic C virus, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, ESRD end-stage renal disease, DAP daptomycin, CEF ceftazidime, MRSA methicillin-resistant Staphylococcus aureus, MRCoNS methicillin-resistant coagulase-negative Staphylococci, MRSE methicillin-resistant Staphylococcus epidermis, FU follow-up